HC Wainwright Has Bearish Forecast for SYRS FY2026 Earnings

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for shares of Syros Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($2.79) for the year, down from their prior estimate of ($2.13). HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($2.94) per share. HC Wainwright also issued estimates for Syros Pharmaceuticals’ FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.25) EPS.

A number of other equities analysts also recently issued reports on SYRS. Piper Sandler reissued an “overweight” rating and set a $5.00 target price (down from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. StockNews.com downgraded Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Stock Performance

Shares of SYRS stock opened at $0.26 on Monday. The company has a market cap of $6.96 million, a price-to-earnings ratio of -0.09 and a beta of 1.59. The stock has a 50 day simple moving average of $1.99 and a 200-day simple moving average of $3.74. Syros Pharmaceuticals has a 12-month low of $0.25 and a 12-month high of $8.17. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the previous year, the company earned ($1.35) EPS.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several hedge funds have recently bought and sold shares of SYRS. Vanguard Group Inc. increased its position in Syros Pharmaceuticals by 21.3% during the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after buying an additional 163,234 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Syros Pharmaceuticals during the first quarter worth $91,000. Kennedy Capital Management LLC acquired a new stake in shares of Syros Pharmaceuticals during the first quarter worth $2,166,000. Virtu Financial LLC acquired a new stake in shares of Syros Pharmaceuticals during the first quarter worth $64,000. Finally, Opaleye Management Inc. boosted its holdings in shares of Syros Pharmaceuticals by 119.1% during the first quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock worth $4,213,000 after purchasing an additional 428,175 shares during the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Insider Activity at Syros Pharmaceuticals

In related news, CFO Jason Haas purchased 45,344 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was bought at an average price of $1.68 per share, with a total value of $76,177.92. Following the completion of the transaction, the chief financial officer now owns 124,552 shares of the company’s stock, valued at approximately $209,247.36. This represents a 57.25 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Conley Chee purchased 50,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were bought at an average cost of $1.51 per share, with a total value of $75,500.00. Following the transaction, the chief executive officer now directly owns 72,504 shares of the company’s stock, valued at $109,481.04. This represents a 222.18 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 130,707 shares of company stock valued at $206,491 in the last ninety days. Corporate insiders own 12.26% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.